Xultophy is commonly used to help manage blood glucose in adults with Type 2 diabetes mellitus. This medicine is applied when other diabetes medicines, alone or with injections, have not provided adequate control of blood sugar levels.

Intensifying Glycemic Control and Supporting Stability

The medicine is used to address two core areas: Intensifying Glycemic Control for inadequate management and Addressing Complexity through regimen simplification. Specifically, Xultophy is relevant for easing persistent high blood glucose, is commonly used to help with high HbA1c levels, and may assist with maintaining functional stability during challenging symptomatic phases. This supportive therapeutic benefit helps address symptoms that may become more disruptive during flare-ups of poor control.

“This therapy is applied across domains where additional symptomatic support is needed when single treatments are no longer providing supportive management.”

Quick Fact: Relief for Inadequate Glycemic Control

Property	Description
Primary Indication	Type 2 Diabetes Mellitus in adults
Symptom Cluster	Persistent hyperglycemia and inadequate long-term metabolic stability
Clinical Scenario	Used when basal insulin or GLP-1 monotherapy fails to provide adequate control
Patient Benefit	Supports the overall symptom burden and contributes to improved comfort during periods of heightened symptoms

The combination provides supportive relief when symptoms that interfere with daily functioning are compounded by a complex treatment plan. By delivering two essential injectable agents in a single injection, the therapy is relevant for supporting the achievement of a more noticeable glucose stability and may assist with maintaining functional stability.

Who Can and Cannot Use Xultophy?

Xultophy is indicated exclusively for adults with Type 2 diabetes mellitus. Use is permissible in elderly patients (aged 65 and older) and in those with mild to moderate kidney or liver impairment; however, these groups require intensified glucose monitoring.

---

Absolute Contraindications

The medicine is strictly contraindicated in several specific populations. It must not be used by patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Use is also prohibited if there is a known hypersensitivity to the active ingredients (insulin degludec, liraglutide) or any excipients. Furthermore, the medicine is not indicated for treating Type 1 diabetes or diabetic ketoacidosis.

---

Regulatory Limitations

Xultophy is not indicated for use in children or adolescents under 18 years of age. Use is generally not recommended for women who are pregnant or breastfeeding. The label also advises against its use in patients with severe hepatic impairment or end-stage renal disease. The medicine must not be combined with any other product containing liraglutide or another GLP-1 receptor agonist.

Xultophy’s officially documented interaction profile is defined by pharmacodynamic effects and specific administration restrictions detailed in regulatory labeling.

Administration Restrictions

The co-administration of Xultophy with any other product containing liraglutide or another GLP-1 receptor agonist is restricted to prevent exceeding the maximum permitted dose of the liraglutide component. Furthermore, therapy with other basal insulins must be formally discontinued prior to starting Xultophy. When transferring from a long-acting GLP-1 receptor agonist, Xultophy initiation must adhere to a mandatory timing rule, beginning when the next scheduled dose of the prior agent would have been due.

Pharmacodynamic and Absorption Effects

Co-administration with sulfonylureas or other glucose-lowering agents increases the risk of hypoglycemia due to additive blood-glucose-lowering effects. Regulatory agencies advise close monitoring and potential dose adjustment of the sulfonylurea. Anti-adrenergic drugs (e.g., beta-blockers) may reduce or mask the warning signs of hypoglycemia. Additionally, the insulin component, when combined with thiazolidinediones (TZDs), has been associated with reports of fluid retention and cardiac failure. The liraglutide component causes a delay in gastric emptying, a physiological effect that may impact the absorption of concomitantly administered oral medications. In terms of substance interactions, alcohol consumption is officially documented as potentially causing unpredictable hypoglycemia or hyperglycemia. The label notes that Xultophy may be administered once daily with or without food. Increased frequency of blood glucose monitoring is required for patients with hepatic or renal impairment due to the heightened risk of hypoglycemia.

Xultophy is a fixed-ratio combination product containing two molecules: the basal insulin analog insulin degludec and the GLP-1 receptor agonist liraglutide. The components engage two distinct, complementary molecular targets.

Insulin degludec monomers bind to and activate the insulin receptor (IR), a cell surface tyrosine kinase. This binding initiates a phosphorylation cascade within the cell, leading to the modulation of downstream metabolic substrates.

Liraglutide selectively binds to and activates the glucagon-like peptide-1 receptor (GLP-1R) on pancreatic beta-cells. The GLP-1R is a G protein-coupled receptor linked to the Galphas subunit. Receptor activation stimulates adenylyl cyclase (AC), which increases the intracellular concentration of cyclic adenosine monophosphate (cAMP). This cAMP-dependent signaling pathway facilitates increased glucose-dependent insulin secretion from beta-cells.

Liraglutide also modulates appetite regulatory pathways centrally and inhibits glucagon secretion from pancreatic alpha-cells peripherally. The dual mechanism of action results in the integrated modulation of glucose-regulating hormones and signaling pathways.

Administration Overview

Xultophy is an injectable medication provided in a pre-filled multidose pen. It is intended for subcutaneous injection only, meaning it is delivered into the fatty tissue layer just beneath the skin. Common injection sites include the thigh, the upper arm, or the abdomen.

Using the Pre-filled Pen

The device is designed to deliver specific doses by adjusting the dose selector on the pen. Before each application, a new disposable needle must be attached to the device. Using a fresh needle for every injection helps prevent contamination and ensures the delivery system functions correctly.

Preparation and Technique

To ensure the medication is delivered properly, the injection site should be rotated within the chosen area. This practice helps reduce the risk of changes to the fatty tissue under the skin, such as thickening or lumps. The medication should appear clear and colorless; if the solution is cloudy or contains particles, the pen should not be used.

Post-Injection Steps

After the injection is complete, the needle must be removed and disposed of safely in a sharps container. The pen should be stored without the needle attached to prevent leakage or the entry of air bubbles into the reservoir.

Storage and Handling

Unused pens should be kept in a controlled, refrigerated environment. Once a pen is in use, it can typically be stored at room temperature or in the refrigerator for a limited period, provided it is kept away from direct heat and light. Always ensure the pen cap is replaced after use to protect the contents from light.

Research Evidence / Overview of Studies for Xultophy

Evidence for Adults Switching from Basal Insulin Therapy

The clinical research program for Xultophy includes short-term, comparative Randomized Controlled Trials (RCTs) that investigated its use in adults with Type 2 Diabetes whose blood sugar measurements were inadequate while on existing basal insulin therapy, often used alongside other oral medications. These studies monitored changes in key blood sugar measurements over a defined time interval.

The research examined shifts in the long-term blood sugar biomarker HbA1c and changes in Fasting Plasma Glucose (FPG) levels. The research also monitored other factors, including body weight patterns and the duration of time before a patient required a change or a decision to intensify their treatment plan. The evidence base for this clinical situation is primarily derived from large-scale Randomized Controlled Trials. However, the research did not include studies where the combination was evaluated in conjunction with prandial (mealtime) insulin therapy. Furthermore, regulatory assessments found that findings regarding the change in FPG levels were mixed across the different trials.

---

Evidence for Adults Transitioning from Oral or GLP-1 Receptor Agonist Therapy

A separate set of Randomized Controlled Trials (RCTs), complemented by systematic reviews, was conducted to explore the evidence for insulin-naïve adults whose condition was not adequately characterized by oral anti-diabetic medications alone, or by a GLP-1 Receptor Agonist with or without oral medications. This research explored short-term changes in biomarkers and studies monitored the combination against its individual components.

Studies monitored changes in the HbA1c biomarker and FPG levels. Other outcomes monitored included measurements of body weight patterns and the duration until a patient needed a decision to intensify their treatment regimen. The evidence in this setting is primarily derived from large-scale Randomized Controlled Trials.

---

Long-Term Research and Durability of Study Findings

The core body of clinical evidence is derived from studies that primarily observed responses over defined time intervals, with pivotal trial phases generally involving follow-up periods of 26 weeks. This research provides insight into short-term changes in the measured blood sugar biomarkers and related measures.

While some extended research tracked patients for up to 104 weeks, data on long-term outcomes beyond the initial pivotal trial periods are not fully established. Therefore, existing studies provide limited information for long-term outcomes regarding the maintenance or durability of the reported measurements. Research is ongoing to better characterize long-term outcomes over many years.

---

Research Gaps and Areas of Uncertainty

One key limitation is that the clinical program does not include studies where the combination was evaluated in conjunction with prandial (mealtime) insulin. This means that data for that specific combination remain insufficient. Additionally, regulatory documentation includes consideration of certain cell findings observed in non-clinical (animal) studies. Research describes the uncertain relevance to humans of these non-clinical findings. Data show patterns related to FPG levels that were mixed or varied across the different conducted trials, indicating an area where certainty remains lower than for the HbA1c biomarker.

Common questions about Xultophy (FAQ)

Q: How does Xultophy lower my blood sugar?

According to official product information, Xultophy lowers blood sugar through the combined action of its two components. The insulin degludec component works to help cells use glucose more effectively. The liraglutide component works by increasing the amount of insulin the pancreas releases in response to glucose and reducing the amount of sugar the liver produces.

Q: Is there a risk of cancer with Xultophy?

Regulatory documents indicate that the liraglutide component of Xultophy caused dose-dependent thyroid C-cell tumors in animal studies. It is not known whether this substance increases the risk of these tumors in humans, which is why official labeling states the medicine is strictly contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Q: Does Xultophy interact with alcohol?

Official information documents that alcohol consumption may cause unpredictable changes in blood sugar levels while using this medicine. This effect could potentially lead to either low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia).

Q: When is the best time of day to take Xultophy?

The injection is designed to be administered once daily at any time of day that is convenient for the patient. However, it is advised that the injection is taken at approximately the same time each day to maintain consistent drug levels in the body.

Q: Can Xultophy cause weight loss?

Studies and official information indicate that patients treated with Xultophy experienced a reduction in mean body weight from baseline during clinical trials. Body weight changes were among the factors tracked during the research phase.

Q: Does Xultophy have a Black Box Warning?

Yes, regulatory documents for Xultophy carry a Boxed Warning—a strong safety warning required by the FDA. This warning specifically concerns the potential risk of thyroid C-cell tumors, a finding observed in animal studies with the liraglutide component.

Q: What are the common injection sites for Xultophy?

The common sites recommended for injection are the abdomen (stomach area), the thigh, or the upper arm. Official guidance advises rotating the exact injection spot within one of these areas for each dose to reduce the risk of localized skin reactions.

How to Store and Dispose of Xultophy?

Storage Requirements

Unopened pens should be stored in a refrigerator between 2 C and 8 C (36 F to 46 F) and kept in the original carton to protect them from light. The product must not be frozen; do not use if it has been frozen.

After first use, the pen can be kept for a maximum of 21 days and stored either at controlled room temperature (up to 30 C or 86 F) or in the refrigerator. After this 21-day period, the pen must be discarded. Always remove the needle after each injection and store the pen with the cap on, without a needle attached, and away from direct heat and light. Keep Xultophy out of the sight and reach of children.

Disposal Instructions

Dispose of used needles in a puncture-resistant container. Do not throw away the pen or any remaining medicine in household waste or wastewater. Consult a pharmacist for proper disposal methods to help protect the environment.